Agilent Technologies had four patents in advanced materials during Q2 2024. Agilent Technologies Inc has developed novel methods for generating and improving MHC multimers, which are used in analyzing T-cells for diagnostic, prognostic, and therapeutic purposes such as anti-tumour and anti-virus therapy. These methods also involve isolating antigen-specific T-cells for inactivating or eliminating target cells, as well as regulating other immune cells. GlobalData’s report on Agilent Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Agilent Technologies had no grants in advanced materials as a theme in Q2 2024.
Recent Patents
Application: Mhc multimers, methods for their generation, labeling and use (Patent ID: US20240150431A1)
The patent filed by Agilent Technologies Inc. describes novel methods for generating MHC multimers and improving existing ones for use in analyzing T-cells in samples, including diagnostic and prognostic applications, as well as in therapy for conditions like anti-tumour and anti-virus treatments. The invention involves compositions of MHC multimers with carrier molecules, where each MHC multimer consists of a functional MHC protein binding to a peptide, associated with multimerization domains and labels such as fluorophores, chromophores, and other markers.
The claims of the patent detail the specific compositions and methods for using the MHC multimers, including the attachment of labels directly or indirectly to the multimers, covalent or non-covalent attachment of labels, and the use of different labels to identify subpopulations of MHC-expressing cells. The patent also covers methods for detecting antigen-specific T cells using the MHC multimers, with options for simultaneously identifying multiple T cell receptors, visualizing different target cells, and performing flow cytometry analysis for detection. Overall, the patent outlines a comprehensive approach to utilizing MHC multimers in various applications related to T-cell analysis and therapy.
To know more about GlobalData’s detailed insights on Agilent Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
